Cadrenal Therapeutics, Inc. (CVKD)
After hours:
| Previous close | 0.4941 |
| Open | 0.4850 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1100 |
| Day's range | 0.4650 - 0.5199 |
| 52-week range | 0.3950 - 6.7500 |
| Volume | |
| Avg. volume | 36,356 |
| Market cap | 6.056M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.00 |
PR NewswireCadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023
Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, announced today that Quang Pham, CEO, will present at NobleCon19 - Noble Capital Markets' Nineteenth (19) Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in B
- PR Newswire
Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update
Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) ("Cadrenal Therapeutics" or the "Company") a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023.
- PR Newswire
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference
Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, announced today that Quang Pham, CEO, will be participating in a Company Webcast and Panel Presentation at the Lytham Partners Fall 2023 Investor Conference on Tuesday, October 17, 2023. Management will also be c
